LALPATHLAB2019-10-012019-12-31in-bse-fin:OneOperatingExpenses01Member LALPATHLAB2019-10-012019-12-31in-bse-fin:OneOperatingExpenses02Member LALPATHLAB2019-10-012019-12-31in-bse-fin:FourOperatingExpenses01Member LALPATHLAB2019-10-012019-12-31in-bse-fin:FourOperatingExpenses02Member LALPATHLAB2019-10-012019-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member LALPATHLAB2019-10-012019-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member LALPATHLAB2019-10-012019-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member LALPATHLAB2019-10-012019-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares LALPATHLAB 2019-04-01 2020-03-31 2020-01-21 INR Millions Third quarter Single segment The business of running laboratories for carrying out Pathological investigations of various branches of Bio-chemistry, Hematology, Histopathology, Microbiology, Electrophoresis, Immuno-chemistry, Immunology, Virology, Cytology, other pathological and radiological investigations. 2019-10-01 2019-12-31 Unaudited Consolidated 3279000000.00 138000000.00 3417000000.00 744000000.00 0.00 0.00 616000000.00 39000000.00 188000000.00 1096000000.00 2683000000.00 734000000.00 0.00 734000000.00 166000000.00 19000000.00 185000000.00 0.00 549000000.00 0.00 0.00 0.00 0.00 549000000.00 1000000.00 550000000.00 541000000.00 8000000.00 542000000.00 8000000.00 833000000.00 10 6.56 6.55 0.00 0.00 6.56 6.55 1.tThe above consolidated results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 3 February, 2020. n2.tThe above consolidated results represent consolidated results of the Company and its subsidiaries (together referred to as 'the Group'). n3.tThese financial results of the Group have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. n4.tEffective 1 April, 2019, Ind AS 116 Leases” has been adopted by the Group using the modified retrospective transition method. Accordingly, the comparatives for earlier periods presented have not been restated. This has resulted in recognising right of use of assets amounting to INR 1477 million and lease liabilities amounting to INR 1320 million. Consequently on transition to Ind AS 116, profit before tax for the current quarter and nine months ended 31 December 2019 is lower by INR 23 million and INR 74 million respectively. n5.tDuring the nine months ended 31 December, 2019, PathLabs Unifiers Private Limited (a wholly owned subsidiary) has purchased the business of “Bawankar Pathology” engaged in the business of providing pathological diagnostics services in Bhandara, on a going concern basis for a purchase consideration of INR 52 million. n6.tAs approved in their meeting held on 7 August, 2019, during the quarter ended 30 September, 2019, the Board of Directors of PathLabs Unifiers Private Limited (a wholly owned subsidiary), acquired an equity stake of 70% in Centrapath Labs Private Limited engaged in pathology business for a consideration of INR 469 Million. n7.tAs approved in their meeting held on 13 November 2019, during the quarter ended 31 December, 2019, the Board of Directors of PathLabs Unifiers Private Limited (a wholly owned subsidiary), acquired an equity stake of 70% in APRL Pathlabs Private Limited engaged in pathology business for a consideration of INR 53 Million. n8.tThe Board of Directors of the Parent Company had approved an interim dividend of INR 6 per equity share (face value of INR 10 each) at their meeting held on 8 November, 2019 which was paid during the quarter ended on 31 December 2019. n9.tThe Board of Directors of the Parent Company and its wholly owned subsidiary Company 'APL Institute of Clinical Laboratory & Research Private Limited' (APL), in their respective meetings held on 3 February, 2020 have approved the “Scheme of Amalgamation” of APL with the Parent Company w.e.f. 1 April, 2020 (the appointed date). As per the said scheme the undertaking of APL shall stand transferred to and vested in the Parent Company on a going concern basis without any further act, deed of matter. The scheme of amalgamation is subject to approval by the shareholder's, National Company Law Tribunal and other statutory approvals. n n10. The Board of Directors of PathLabs Unifiers Private Limited (a wholly owned subsidiary) in their meeting held on 3 February, 2020, has approved signing of binding term sheets for acquisition of business of “M/s Shree Computerised Pathology Laboratory” in Yavatmal and “Modern Diagnostics & Modern Lab” in Sangli, engaged in the business of providing pathological diagnostics services in the state of Maharashtra, on a going concern basis for a purchase consideration not exceeding of INR 41 million and INR 36 million respectively. n n11. For note no. 11 please refer attached PDF consolidated financials for the period ended December 31, 2019. (due to size constraint) Single segment 2019-04-01 2019-12-31 Unaudited Consolidated 10287000000.00 430000000.00 10717000000.00 2267000000.00 0.00 0.00 1801000000.00 114000000.00 528000000.00 3356000000.00 8066000000.00 2651000000.00 0.00 2651000000.00 679000000.00 22000000.00 701000000.00 0.00 1950000000.00 0.00 0.00 0.00 0.00 1950000000.00 11000000.00 1961000000.00 1934000000.00 16000000.00 1945000000.00 16000000.00 833000000.00 10 23.48 23.42 0.00 0.00 23.48 23.42 Fees to collection centers/channel partners 421000000.00 Other expenses 675000000.00 Fees to collection centers/channel partners 1337000000.00 Other expenses 2019000000.00